Publication of Theraclion's adjusted accounts for the first half of 2024

Theraclion, a specialist in high-intensity focused ultrasound therapy, has published its adjusted financial statements for the first half of 2024. The company has refocused on the varicose veins market, ceasing the marketing of its Echopulse thyroid machines. This decision led to the issuance of a €680,000 credit note to its joint venture in China, negatively impacting its results.

Adjusted revenue is negative at -€238K, compared to €981K last year. Adjusted gross margin falls to -€7K. Adjusted operating income goes from -€2,987K to -€3,665K. Theraclion has cash of €4.1M, sufficient until the second quarter of 2025, but is seeking financing to ensure its continuity.